These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38609650)

  • 1. Bile Acid-Targeted Hyaluronic Acid Nanoparticles for Enhanced Oral Absorption of Deferoxamine.
    Agboluaje EO; Cui S; Grimsey NJ; Xiong MP
    AAPS J; 2024 Apr; 26(3):46. PubMed ID: 38609650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
    Liu Z; Lin TM; Purro M; Xiong MP
    ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis.
    S V; A S; Annapoorna M; R J; Subramania I; Shantikumar V N; R J
    Colloids Surf B Biointerfaces; 2018 Jan; 161():129-138. PubMed ID: 29055865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption.
    Cui S; Liu Z; Nagy T; Agboluaje EO; Xiong MP
    Mol Pharm; 2023 Feb; 20(2):1285-1295. PubMed ID: 36622899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoting tissue repair using deferoxamine nanoparticles loaded biomimetic gelatin/HA composite hydrogel.
    Li J; Lu X; Weng M; Wang Y; Tang J; Xu Q; Zhang L; Bai J
    Biomed Mater; 2024 May; 19(4):. PubMed ID: 38697149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
    Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
    Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
    Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
    Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive Oxygen Species-Triggered Dissociation of a Polyrotaxane-Based Nanochelator for Enhanced Clearance of Systemic and Hepatic Iron.
    Liu Z; Simchick GA; Qiao J; Ashcraft MM; Cui S; Nagy T; Zhao Q; Xiong MP
    ACS Nano; 2021 Jan; 15(1):419-433. PubMed ID: 33378155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine.
    Michailidou G; Li Y; Zamboulis A; Karlioti G; Meimaroglou D; Pantopoulos K; Bikiaris DN
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
    Liu Z; Qiao J; Nagy T; Xiong MP
    J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiently suppress of ferroptosis using deferoxamine nanoparticles as a new method for retinal ganglion cell protection after traumatic optic neuropathy.
    Lin S; Gao W; Zhu C; Lou Q; Ye C; Ren Y; Mehmood R; Huang B; Nan K
    Biomater Adv; 2022 Jul; 138():212936. PubMed ID: 35913229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
    Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.